• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist.

作者信息

Tunney Michael M, Wark Peter

机构信息

Halo Research Group, School of Pharmacy, Queen's University Belfast, Belfast, UK

College of Health Medicine and Wellbeing, University of Newcastle, New Lambton, Australia.

出版信息

Eur Respir J. 2023 Aug 3;62(2). doi: 10.1183/13993003.01008-2023. Print 2023 Aug.

DOI:10.1183/13993003.01008-2023
PMID:37536727
Abstract
摘要

相似文献

1
Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist.依列卡福妥/替扎卡福妥/依伐卡托（ETI）用于囊性纤维化的长期治疗：临床结局改善，但感染和炎症仍然存在。
Eur Respir J. 2023 Aug 3;62(2). doi: 10.1183/13993003.01008-2023. Print 2023 Aug.
2
Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis.依伐卡托/泰他卡托/艾美卡替三联复方制剂对囊性纤维化患者痰液黏弹性特性、气道感染和炎症的纵向影响。
Eur Respir J. 2023 Aug 3;62(2). doi: 10.1183/13993003.02153-2022. Print 2023 Aug.
3
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
4
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
5
Physiologically Based Pharmacokinetic Modeling To Guide Management of Drug Interactions between Elexacaftor-Tezacaftor-Ivacaftor and Antibiotics for the Treatment of Nontuberculous Mycobacteria.基于生理的药代动力学模型指导依非韦伦、泰诺福韦和艾维雷韦与抗生素联合治疗非结核分枝杆菌药物相互作用的管理
Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0110422. doi: 10.1128/aac.01104-22. Epub 2022 Oct 26.
6
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.依列卡福妥联合替扎卡福妥和依伐卡托对比替扎卡福妥联合依伐卡托治疗F508del-CFTR纯合子囊性纤维化患者的疗效和安全性：一项为期24周的多中心、随机、双盲、活性对照3b期试验
Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20.
7
Triple Therapy for Cystic Fibrosis -Gating and -Residual Function Genotypes.囊性纤维化-门控和-残留功能基因型的三联疗法。
N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665.
8
Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy.依伐卡托与泰他卡托和艾乐卡托联合治疗囊性纤维化成人患者中的调节性 T 细胞增强作用。
Front Immunol. 2023 Feb 16;14:1107437. doi: 10.3389/fimmu.2023.1107437. eCollection 2023.
9
Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19.基于生理的药代动力学引导用于 COVID-19 治疗中接受 Elexacaftor-Tezacaftor-Ivacaftor 联合奈玛特韦-利托那韦治疗的囊性纤维化患者。
Clin Pharmacol Ther. 2022 Jun;111(6):1324-1333. doi: 10.1002/cpt.2585. Epub 2022 Apr 6.
10
Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.接受依利尤单抗治疗的囊性纤维化患者肺功能进展的临床预测因素分析。
Respir Med Res. 2021 Nov;80:100829. doi: 10.1016/j.resmer.2021.100829. Epub 2021 May 17.

引用本文的文献

1
Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis.依列卡福妥/替扎卡福妥/依伐卡托对骨密度和身体成分的影响：一项回顾性分析
Pediatr Pulmonol. 2025 Sep;60(9):e71280. doi: 10.1002/ppul.71280.
2
Linking volatile metabolites from bacterial pathogens to exhaled breath condensate of people with cystic fibrosis.将细菌病原体的挥发性代谢物与囊性纤维化患者的呼出气体冷凝物联系起来。
Microbiology (Reading). 2025 Feb;171(2). doi: 10.1099/mic.0.001536.
3
Impact of lumacaftor/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: a prospective multicenter cohort study in Sweden.
卢美他尼/依伐卡托对囊性纤维化患者呼吸道细菌和真菌病原体的影响：瑞典一项前瞻性多中心队列研究。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241254090. doi: 10.1177/17534666241254090.
4
Airway inflammation accelerates pulmonary exacerbations in cystic fibrosis.气道炎症会加速囊性纤维化患者的肺部病情恶化。
iScience. 2024 Jan 9;27(3):108835. doi: 10.1016/j.isci.2024.108835. eCollection 2024 Mar 15.
5
Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.依伐卡托与泰它西普和艾乐卡托联合治疗囊性纤维化肺部后纵向微生物和分子动态变化
Respir Res. 2023 Dec 16;24(1):317. doi: 10.1186/s12931-023-02630-z.
6
Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.依列卡福妥-替扎卡福妥-依伐卡福妥治疗后囊性纤维化肺部的纵向微生物和分子动力学
Res Sq. 2023 Sep 25:rs.3.rs-3356170. doi: 10.21203/rs.3.rs-3356170/v1.